{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:49:01Z","timestamp":1793875741051,"version":"4.7.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with oligomonocytic chronic myelomonocytic leukemia (OM-CMML) are currently classified according to the 2017 World Health Organization myelodysplastic syndromes classification. However, recent data support considering OM-CMML as a specific subtype of chronic myelomonocytic leukemia (CMML), given their similar clinical, genomic, and immunophenotypic profiles. The main purpose of our study was to provide survival outcome data of a well-annotated series of 42 patients with OM-CMML and to compare them to 162 patients with CMML, 120 with dysplastic type (D-CMML), and 42 with proliferative type (P-CMML). OM-CMML had significantly longer overall survival (OS) and acute myeloid leukemia\u2013free survival than did patients with CMML, considered as a whole group, and when compared with D-CMML and P-CMML. Moreover, gene mutations associated with increased proliferation (ie, ASXL1 and RAS-pathway mutations) were identified as independent adverse prognostic factors for OS in our series. We found that at a median follow-up of 53.47 months, 29.3% of our patients with OM-CMML progressed to D-CMML, and at a median follow-up of 46.03 months, 28.6% of our D-CMML group progressed to P-CMML. These data support the existence of an evolutionary continuum of OM-CMML, D-CMML, and P-CMML. In this context, we observed that harboring more than 3 mutated genes, carrying ASXL1 mutations, and a peripheral blood monocyte percentage &amp;gt;20% significantly predicted a shorter time of progression of OM-CMML into overt CMML. These variables were also detected as independent adverse prognostic factors for OS in OM-CMML. These data support the consideration of OM-CMML as the first evolutionary stage within the proliferative continuum of CMML.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007359","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T20:12:34Z","timestamp":1655410354000},"page":"3921-3931","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-9130","authenticated-orcid":false,"given":"Xavier","family":"Calvo","sequence":"first","affiliation":[{"name":"1Laboratori de Citologia Hematol\u00f2gica, Servei de Patologia, Grup de Recerca Translacional en Neopl\u00e0sies Hematol\u00f2giques (GRETNHE), Hospital del Mar Research Institute (IMIM), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roman-Bravo","sequence":"additional","affiliation":[{"name":"1Laboratori de Citologia Hematol\u00f2gica, Servei de Patologia, Grup de Recerca Translacional en Neopl\u00e0sies Hematol\u00f2giques (GRETNHE), Hospital del Mar Research Institute (IMIM), Barcelona, Spain;"},{"name":"2Servei d\u2019Hematologia Cl\u00ednica, Grup de Recerca Cl\u00ednica Aplicada en Neopl\u00e0sies Hematol\u00f2giques, IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8185-9786","authenticated-orcid":false,"given":"Nieves","family":"Garcia-Gisbert","sequence":"additional","affiliation":[{"name":"3Laboratori de Biologia Molecular, Servei de Patologia, Grup de Recerca Cl\u00ednica Aplicada en Neopl\u00e0sies Hematol\u00f2giques, IMIM, Barcelona, Spain;"},{"name":"4Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-7925","authenticated-orcid":false,"given":"Juan Jose","family":"Rodriguez-Sevilla","sequence":"additional","affiliation":[{"name":"1Laboratori de Citologia Hematol\u00f2gica, Servei de Patologia, Grup de Recerca Translacional en Neopl\u00e0sies Hematol\u00f2giques (GRETNHE), Hospital del Mar Research Institute (IMIM), Barcelona, Spain;"},{"name":"2Servei d\u2019Hematologia Cl\u00ednica, Grup de Recerca Cl\u00ednica Aplicada en Neopl\u00e0sies Hematol\u00f2giques, IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garcia-Avila","sequence":"additional","affiliation":[{"name":"2Servei d\u2019Hematologia Cl\u00ednica, Grup de Recerca Cl\u00ednica Aplicada en Neopl\u00e0sies Hematol\u00f2giques, IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Florensa","sequence":"additional","affiliation":[{"name":"1Laboratori de Citologia Hematol\u00f2gica, Servei de Patologia, Grup de Recerca Translacional en Neopl\u00e0sies Hematol\u00f2giques (GRETNHE), Hospital del Mar Research Institute (IMIM), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-0759","authenticated-orcid":false,"given":"Joan","family":"Gibert","sequence":"additional","affiliation":[{"name":"3Laboratori de Biologia Molecular, Servei de Patologia, Grup de Recerca Cl\u00ednica Aplicada en Neopl\u00e0sies Hematol\u00f2giques, IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"3Laboratori de Biologia Molecular, Servei de Patologia, Grup de Recerca Cl\u00ednica Aplicada en Neopl\u00e0sies Hematol\u00f2giques, IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-5977","authenticated-orcid":false,"given":"Marta","family":"Salido","sequence":"additional","affiliation":[{"name":"5Laboratori de Gen\u00e8tica Molecular, Servei de Patologia, GRETNHE, IMIM, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-4978","authenticated-orcid":false,"given":"Anna","family":"Puiggros","sequence":"additional","affiliation":[{"name":"5Laboratori de Gen\u00e8tica Molecular, Servei de Patologia, GRETNHE, IMIM, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-8145","authenticated-orcid":false,"given":"Blanca","family":"Espinet","sequence":"additional","affiliation":[{"name":"5Laboratori de Gen\u00e8tica Molecular, Servei de Patologia, GRETNHE, IMIM, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-5085","authenticated-orcid":false,"given":"Luis","family":"Colomo","sequence":"additional","affiliation":[{"name":"4Universitat Pompeu Fabra, Barcelona, Spain;"},{"name":"6Secci\u00f3 d\u2019Hematopatologia, Servei de Patologia, GRETNHE, IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-2726","authenticated-orcid":false,"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[{"name":"3Laboratori de Biologia Molecular, Servei de Patologia, Grup de Recerca Cl\u00ednica Aplicada en Neopl\u00e0sies Hematol\u00f2giques, IMIM, Barcelona, Spain;"},{"name":"4Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-9472","authenticated-orcid":false,"given":"Ana","family":"Ferrer","sequence":"additional","affiliation":[{"name":"1Laboratori de Citologia Hematol\u00f2gica, Servei de Patologia, Grup de Recerca Translacional en Neopl\u00e0sies Hematol\u00f2giques (GRETNHE), Hospital del Mar Research Institute (IMIM), Barcelona, Spain;"},{"name":"4Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-7179","authenticated-orcid":false,"given":"Leonor","family":"Arenillas","sequence":"additional","affiliation":[{"name":"1Laboratori de Citologia Hematol\u00f2gica, Servei de Patologia, Grup de Recerca Translacional en Neopl\u00e0sies Hematol\u00f2giques (GRETNHE), Hospital del Mar Research Institute (IMIM), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"issue":"9","key":"2022070615215714400_B1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","article-title":"Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol."},{"issue":"10","key":"2022070615215714400_B2","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions","volume":"104","author":"Valent","year":"2019","journal-title":"Haematologica."},{"issue":"20","key":"2022070615215714400_B3","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/bloodadvances.2020002206","article-title":"Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features","volume":"4","author":"Calvo","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2022070615215714400_B4","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1002\/ajh.26044","article-title":"Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia","volume":"96","author":"Montalban-Bravo","year":"2021","journal-title":"Am J Hematol."},{"issue":"3","key":"2022070615215714400_B5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood."},{"issue":"15","key":"2022070615215714400_B6","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood."},{"issue":"19","key":"2022070615215714400_B7","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022070615215714400_B8","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia."},{"issue":"11","key":"2022070615215714400_B9","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia."},{"issue":"11","key":"2022070615215714400_B10","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.leukres.2015.05.017","article-title":"Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML","volume":"39","author":"Calvo","year":"2015","journal-title":"Leuk Res."},{"issue":"7","key":"2022070615215714400_B11","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J."},{"issue":"10","key":"2022070615215714400_B12","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood."},{"issue":"6","key":"2022070615215714400_B13","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"issue":"12","key":"2022070615215714400_B14","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood."},{"key":"2022070615215714400_B15","volume-title":"WHO Classification of Tumours.","author":"Swerdlow","year":"2017","edition":"4th ed"},{"issue":"20","key":"2022070615215714400_B16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"issue":"23","key":"2022070615215714400_B17","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood."},{"issue":"6","key":"2022070615215714400_B18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2017-04-779579","article-title":"Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML","volume":"130","author":"Selimoglu-Buet","year":"2017","journal-title":"Blood."},{"issue":"13","key":"2022070615215714400_B19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2016-12-753210","article-title":"Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis","volume":"129","author":"Talati","year":"2017","journal-title":"Blood."},{"key":"2022070615215714400_B20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fonc.2018.00109","article-title":"Evaluation by flow cytometry of mature monocyte subpopulations for the diagnosis and follow-up of chronic myelomonocytic leukemia","volume":"8","author":"Picot","year":"2018","journal-title":"Front Oncol."},{"issue":"4","key":"2022070615215714400_B21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ajcp\/aqy054","article-title":"Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia","volume":"150","author":"Hudson","year":"2018","journal-title":"Am J Clin Pathol."},{"issue":"11","key":"2022070615215714400_B22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-018-0146-8","article-title":"Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis","volume":"8","author":"Tarfi","year":"2018","journal-title":"Blood Cancer J."},{"issue":"4","key":"2022070615215714400_B23","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.3324\/haematol.2019.219782","article-title":"Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with associated inflammatory state","volume":"105","author":"Tarfi","year":"2019","journal-title":"Haematologica."},{"issue":"3","key":"2022070615215714400_B24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica."},{"issue":"1","key":"2022070615215714400_B25","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun."},{"issue":"12","key":"2022070615215714400_B26","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood."},{"issue":"7","key":"2022070615215714400_B27","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An evolutionary perspective on chronic myelomonocytic leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia."},{"issue":"6","key":"2022070615215714400_B28","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.3324\/haematol.2018.208082","article-title":"Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation","volume":"104","author":"Patnaik","year":"2019","journal-title":"Haematologica."},{"issue":"7","key":"2022070615215714400_B29","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1038\/bcj.2017.66","article-title":"Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis","volume":"7","author":"Patnaik","year":"2017","journal-title":"Blood Cancer J."},{"key":"2022070615215714400_B30","doi-asserted-by":"crossref","first-page":"106771","DOI":"10.1016\/j.leukres.2021.106771","article-title":"Monocyte subset distribution in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms with monocytosis","volume":"112","author":"Sorigue","year":"2022","journal-title":"Leuk Res."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3921\/1905490\/advancesadv2022007359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3921\/1905490\/advancesadv2022007359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T15:22:23Z","timestamp":1657120943000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/13\/3921\/485125\/Outcomes-and-molecular-profile-of-oligomonocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,7,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007359","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}